Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2020/1025913 http://scihub22266oqcxt.onion/10.1155/2020/1025913 33145103!7596458!33145103     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Hypertens 2020 ; 2020 (ä): 1025913 Nephropedia Template TP {{tp|p=33145103|t=2020. Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts |pdf=|usr=}}{{33145103}} gab.com Text Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts JO: Int J Hypertens http://www.kidney.de/pget.php?&tw=1&pmid=33145103 #FOAvip The functional receptor to SARS-CoV-2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is angiotensin-converting enzyme-2 (ACE-2), the same enzyme that physiologically counters the renin-angiotensin system (RAS) activation. Some researchers have questioned RAS inhibitors' safety in COVID-19 patients since these drugs have demonstrated an increase in ACE-2 expression in preclinical studies; therefore, they may facilitate viral invasion. On the contrary, others have hypothesized a protective role of RAS inhibitors against COVID-19-associated lung injury. Overall, the data are grossly inadequate to reach any conclusion since no human trials have yet evaluated the effects of RAS inhibitors in COVID-19. We review the current data and pathophysiological mechanisms behind this intriguing interplay between the RAS inhibitors and the COVID-19. Twit Text FOAVip Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts ????Int J Hypertens http://www.kidney.de/pget.php?&tw=1&pmid=33145103 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33145103 #FOAvip English Wikipedia <ref>{{Cite pmid|33145103}}</ref> Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts #MMPMID33145103 Mahajan K; Chand Negi P; Ganju N; Sondhi S; Gaur N; Somendra R Int J Hypertens 2020[]; 2020 (ä): 1025913 PMID33145103show ga The functional receptor to SARS-CoV-2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is angiotensin-converting enzyme-2 (ACE-2), the same enzyme that physiologically counters the renin-angiotensin system (RAS) activation. Some researchers have questioned RAS inhibitors' safety in COVID-19 patients since these drugs have demonstrated an increase in ACE-2 expression in preclinical studies; therefore, they may facilitate viral invasion. On the contrary, others have hypothesized a protective role of RAS inhibitors against COVID-19-associated lung injury. Overall, the data are grossly inadequate to reach any conclusion since no human trials have yet evaluated the effects of RAS inhibitors in COVID-19. We review the current data and pathophysiological mechanisms behind this intriguing interplay between the RAS inhibitors and the COVID-19. äRenin-Angiotensin System Inhibitors in COVID-19: Current Concepts (epmc).pdf DeepDyve Pubget Overpricing